Clinical data | |
---|---|
Other names | Beta-methyl-6-chloromelatonin; LY-156735; PD-6735 |
Routes of administration | Oral |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Elimination half-life | 1 hour |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C14H17ClN2O2 |
Molar mass | 280.75 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
TIK-301 (LY-156735) is an agonist for the melatonin receptors MT1 and MT2 that is under development for the treatment of insomnia and other sleep disorders.[1] Its agonist action on MT1 and MT2 receptors in the suprachiasmatic nucleus in the brain enables its action as a chronobiotic. It is in the same class of melatonin receptor agonists as ramelteon and tasimelteon.